Health committee  Let me be clear: The answer is never.

Health committee  Again, I can't speak to other countries and the unique circumstances that led to disclosures for Pfizer or any other company.

Health committee  Pfizer has provided an unprecedented level of transparency. We've openly shared details of our clinical program. We've published data in peer-reviewed journals. We've shared our manufacturing targets and performance against them.

Health committee  This balances the need—

Health committee  Again, terms and conditions of the Canadian contract should remain confidential.

Health committee  Because of the geopolitical sensitivities. As I've mentioned earlier, we've negotiated with each country outside of the EU on an individual basis given its unique circumstances. Diving into the details of contracts will not bring vaccines to Canada any quicker, so we strongly rec

Health committee  As I mentioned earlier we do have a pricing tier that is reflective of a country's income level. Thirty-six per cent of our contracted volumes are for middle- and low-income countries, and we have made a 40-million dose commitment to COVAX. We also support the Government of Canad

Health committee  Again, I can't discuss any price.

Health committee  Pfizer has been on record from the beginning to say that traditional supply and demand economics do not factor into our pricing decision.

Health committee  Again, I appreciate the question, but we will not be discussing pricing publicly.

Health committee  That's correct.

Health committee  We began negotiating in mid-November when both we and the government identified a potential pathway to an earlier decision, and concluded that negotiation in December.

Health committee  In terms of the benchmarks that are often used, both the U.K. and the U.S. anticipated much earlier in the pandemic a potential pathway for a December authorization—

Health committee  It was some time in mid-November.

Health committee  Prices are confidential and we will not be sharing them.